Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. (26th October 2021)

• Record Type: Journal Article
• Authors: Elston, Marianne S.; Love, Amanda; Kevat, Dev; Carroll, Richard; Siow, Zhen Rong; Pattison, Sharon; Boyle, Veronica; Segelov, Eva; Strickland, Andrew H.; Wyld, David; Gauci, Richard; Kennedy, Kim; Ransom, David
• Is Part Of: Cancer medicine. Volume 10:Number 23(2021)
• Page Start: 8405
• Page End: 8411
• Publication Date: 2021-10-26
• Subjects: hypogonadism -- hypopituitarism -- neuroendocrine tumours -- radioisotopes -- receptor -- somatostatin; 616.994005
• DOI: 10.1002/cam4.4345
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism. The aim was to assess the prevalence of clinically significant hypopituitarism a minimum of 2 years following radioisotope therapy for metastatic NET. This was a multicentre study (Australia and New Zealand). Sixty‐six patients with unresectable NETs were included–34 had received PRRT and 32 comparison patients. Median follow‐up after PRRT was 68 months. Male hypogonadism was the most common hormonal abnormality (16 of 38 men [42%]) from the total cohort. Of these, seven men had primary hypogonadism (five from PRRT group) and nine had secondary hypogonadism (six in PRRT group). There was no difference in either male hypogonadism or other hormonal dysfunction between patients who had received PRRT and those that had not. Patients who have received PRRT out to 68 months following treatment do not show concerning hypopituitarism although there may be the suggestion of growth hormone deficiency developing. However, hypogonadism is common in men with NETs so the gonadal axis should be assessed in men with suggestive symptoms as the treatment of testosterone deficiency may improve the quality of life. Abstract : Graphical representation of physiological pituitary activity on Gallium 68‐DOTA‐Octreotate PET/CT.